Introduction: The efficacy and safety of the once–daily topical ophthalmic solutions, alcaftadine 0.25% and olopatadine 0.2%, in preventing ocular itching associated with allergic conjunctivitis were evaluated. Ocular itching, the hallmark symptom of allergic conjunctivitis, is often accompanied by tearing, conjunctival redness, eyelid swelling, and chemosis. Both olopatadine and alcaftadine are classified as dual–action antiallergic agents

Materials & Method: After patient selection of suspected  allergic conjuctivitis sociodemographic data risk factors and clinical symptoms were recorded. Ophthalmic examination was performed including records details of symptoms, drugs used, visual acuity and slit lamp examination. Patients categorized according symptoms and prescribed them alcaftadine 0.25% in one eye and olopatadine 0.2%in another eye and Drug original label are removed and drug is label as 1 or 2. Patient were be followed up at 1 hour,  3 ^rd days, 1 week and 3week.

Results: Male preponderance was seen in the ratio 2.33:1.Mean  age was 25.8 years. Itching and redness is present in all 100% cases . 100% improvement in all sign and symptoms  at last follow up(3week).

Conclusion:  Compared with olopatadine 0.2% ophthalmic solution, treatment with alcaftadine 0.25% ophthalmic solution provided greater relief of ocular itching at post–administration with a similar safety profile.  But  statically not significant  (p value >0.05) difference in no. of patients which shows improvementin sign and symptoms, treated with alcaftadine 0.25% compare of olopatadine 0.2%.